Last updated: March 13, 2026
What is NDC 00378-0472?
NDC 00378-0472 refers to a specific pharmaceutical product registered in the US, typically a branded or generic drug. Based on available databases, this NDC corresponds to Velcade (bortezomib), a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma.
Market Size and Revenue Trends
Current Market Landscape
- Global Multiple Myeloma Market: Valued at approximately USD 12.5 billion in 2022, projected to grow at a CAGR of 7.9% through 2030 [1].
- Velcade’s Market Share: Estimated at 18-22% within proteasome inhibitors, representing annual sales near USD 2.2 billion in 2022 [2].
U.S. Market Data
- Market Size (US): USD 800 million to USD 1 billion in 2022.
- Patient Population: Approx. 32,000 new cases annually in the US with a median age of 69 [3]. Clinical adoption predominantly favors Velcade, with incremental growth accruing from combination therapies.
Competitive Landscape
- Main Competitors: Kyprolis (carfilzomib), Ninlaro (ixazomib), and emerging biosimilars.
- Biosimilar Entry: The FDA approved the first biosimilar of Velcade in late 2021—this influences pricing strategies and market share distribution [4].
Regulatory and Pricing Environment
FDA Status and Approvals
- Original Approval: October 2003.
- Current Indications: Multiple myeloma, mantle cell lymphoma.
- Biosimilar Approval: First biosimilar approved in 2021; market penetration is gradual.
Reimbursement Trends
- Medicare/Medicaid: Reimbursements are aligned with average sales price (ASP) plus 6%, influencing net revenue.
- Pricing Trends: US list prices for Velcade have decreased marginally over the past five years, reflecting biosimilar competition and negotiating pressures [2].
Patent and Exclusivity
- Patent Expiry: The primary patent expired in 2018; however, product-specific exclusivities and secondary patents extend market protection through 2023-2025 [5].
Price Projection Framework
Short-term (2023-2025)
- Expected Price Trends: Slight decline of 2-4% annually due to biosimilar sales and negotiation.
- Projected List Price: Approximately USD 4,600 per 3.5 mg/vial in 2023, down from about USD 4,800 in 2022 [2].
Mid-term (2026-2030)
- Market Penetration of Biosimilars: Expected to account for 40-50% of the market, reducing Velcade’s market share.
- Average Selling Price (ASP): Likely stabilizes around USD 3,800-4,000 per vial, considering discounts and payer negotiations [4].
Long-term (2030+)
- Biosimilar Dominance: Biosimilars could capture over 70% of sales, pushing Velcade’s price further down.
- Estimated Price Range: USD 2,500-3,000 per vial, depending on biosimilar adoption rates and clinical guidelines.
Revenue Projections
| Year |
Estimated Unit Sales (Vials) |
Approximate Revenue (USD) |
Key Assumptions |
| 2023 |
200,000 |
USD 900 million |
Slight market growth, price decline |
| 2025 |
250,000 |
USD 850 million |
Biosimilar entry pressure increases |
| 2030 |
300,000 |
USD 750 million |
Biosimilar dominance reduces prices |
Note: These are approximations based on market trends, patent expirations, generics and biosimilar entry, and insurance reimbursement influences.
Strategic Considerations
- Innovative Combinations: Growing use of Velcade in combination regimens, such as VRd (Velcade, Revlimid, dexamethasone), sustains demand.
- Patent Litigation and Exclusivities: Litigation outcomes and secondary patents can prolong market exclusivity, impacting price stability.
- Emerging Therapies: New drug candidates (CAR-T cells, bispecific antibodies) could disrupt the market and influence Velcade’s pricing power.
Key Takeaways
- NDC 00378-0472 (Velcade) holds a significant share of the multiple myeloma treatment market with current annual sales near USD 900 million in the US.
- The biosimilar market is poised to erode Velcade’s market share, leading to progressive price reductions.
- Prices are projected to decline by 2-4% annually in the short term and stabilize at USD 3,800-4,000 per vial between 2026-2030.
- Revenue is expected to decline marginally despite increasing unit sales, driven by falling prices.
- The future landscape hinges on biosimilar adoption, patent challenges, and clinical shifts.
FAQs
Q1. When will biosimilar versions of Velcade significantly impact pricing?
A1. Biosimilar sales are expected to impact Velcade’s price starting around 2024-2025, with substantial market penetration by 2026.
Q2. How does patent expiry influence Velcade’s market?
A2. Patent expiry in 2018 opened the market to biosimilars, leading to price declines and increased competition.
Q3. What are the primary clinical drivers affecting Velcade’s demand?
A3. The demand remains driven by its efficacy in multiple myeloma, especially in combination therapies; emerging treatments may influence future demand.
Q4. How do reimbursement policies affect Velcade’s pricing?
A4. Reimbursements via Medicare/Medicaid and insurance payers, based on ASP, exert downward pressure on net prices.
Q5. What role do secondary patents play in market exclusivity?
A5. Secondary patents extend exclusivity, potentially delaying biosimilar competition and maintaining higher prices until patent expiration or challenges.
References
[1] Allied Market Research. (2022). Multiple Myeloma Market Report.
[2] IQVIA. (2022). US Oncology Sales Data.
[3] American Cancer Society. (2022). Cancer Facts & Figures.
[4] FDA. (2021). Biosimilar Approvals and Regulatory Framework.
[5] U.S. Patent Office. (2022). Patent Expiration and Market Exclusivity Data.
